高频振荡通气治疗急性呼吸窘迫综合征的异质性效应:OSCILLATE 试验的事后分析
该研究为 OSCILLATE 随机对照试验的事后分析,纳入 39 个 ICU、5 个国家的 548 例中重度 ARDS 成人患者,比较高频振荡通气(HFOV)与低潮气量、较高呼气末正压的常规机械通气。原试验发现 HFOV 增加住院死亡风险(主要结局)。本分析采用三种方法评估疗效异质性:基于基线 PaO2:FIO2 比值和氧合指数的亚组分析、基于多变量结局预测模型的风险分层、以及多变量潜在类别分析聚类。结果显示 HFOV 对住院死亡率的影响在各亚组间一致,交互作用均无统计学意义,未发现异质性。
要点
- 在 PaO2:FIO2 ≥80 组,HFOV 对住院死亡率的校正 OR 为 2.04(95%CI 1.32-3.17);<80 组 aOR 1.16(95%CI 0.49-2.75);交互作用 P=0.23。
- 按基线氧合指数四分位分组,HFOV 效应分别为 aOR 1.78(95%CI 0.67-4.70)、3.19(95%CI 1.44-7.09)、1.73(95%CI 0.82-3.65)、1.33(95%CI 0.61-2.90),交互作用 P=0.44。
- 按风险预测模型分低、中、高风险组,HFOV 效应 aOR 分别为 2.44(95%CI 0.40-14.83)、1.69(95%CI 0.75-3.85)、2.10(95%CI 0.59-7.54),交互作用 P=0.32。
- 潜在类别分析得到 2 个聚类:聚类1 aOR 1.85(95%CI 1.15-3.00),聚类2 aOR 1.75(95%CI 0.91-3.38),交互作用 P=0.75。
- 作者结论:未发现 HFOV 效应在不同 ARDS 亚组中存在异质性。
适用人群与场景
- 39 个 ICU、5 个国家的 548 例中重度 ARDS 成人患者。
研究设计与关键结果
- 研究设计:OSCILLATE 随机对照试验的事后分析。
- 干预与对照:HFOV vs. 低潮气量、较高呼气末正压的常规机械通气。
- 主要终点:住院死亡率;原试验发现 HFOV 增加住院死亡风险。
- 按基线 PaO2:FIO2 比值分层:≥80 组 aOR 2.04(95%CI 1.32-3.17);<80 组 aOR 1.16(95%CI 0.49-2.75);交互作用 P=0.23。
- 按基线氧合指数四分位分层:第1四分位 aOR 1.78(95%CI 0.67-4.70);第2四分位 aOR 3.19(95%CI 1.44-7.09);第3四分位 aOR 1.73(95%CI 0.82-3.65);第4四分位 aOR 1.33(95%CI 0.61-2.90);交互作用 P=0.44。
- 按风险预测模型分层:最低风险组 aOR 2.44(95%CI 0.40-14.83);中等风险组 aOR 1.69(95%CI 0.75-3.85);最高风险组 aOR 2.10(95%CI 0.59-7.54);交互作用 P=0.32。
- 潜在类别分析聚类:聚类1 aOR 1.85(95%CI 1.15-3.00);聚类2 aOR 1.75(95%CI 0.91-3.38);交互作用 P=0.75。
证据类型、等级与局限
- 证据类型:随机对照试验的事后分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 该事后分析未发现 HFOV 效应在不同亚组中存在异质性,各亚组点估计均显示 HFOV 无获益,不支持根据 PaO2:FIO2、氧合指数、风险分层或潜在类别选择患者使用 HFOV。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: We sought to evaluate whether different subgroups of adults with acute respiratory distress syndrome (ARDS) respond differently to high-frequency oscillatory ventilation (HFOV).
DESIGN: The Oscillation for ARDS Treated Early (OSCILLATE) trial was a randomized controlled trial of HFOV vs. conventional ventilation that found an increased risk of in-hospital mortality (primary outcome) with HFOV. In a post hoc analysis, we applied three different approaches to evaluate heterogeneity of treatment effect for in-hospital mortality: 1) subgroup analyses based on baseline Pao2:Fio2 ratio and oxygenation index (OI); 2) a risk-based approach using a multivariable outcome prediction model; and 3) a clustering approach via multivariable latent class analysis. We used multivariable logistic regression models to assess for interaction.
SETTING: Thirty-nine ICUs, five countries.
SUBJECTS: Five hundred forty-eight adults with moderate to severe ARDS.
INTERVENTIONS: HFOV vs. conventional mechanical ventilation with low tidal volume and higher positive end-expiratory pressure.
MEASUREMENTS AND MAIN RESULTS: The effect of HFOV on in-hospital mortality was consistent across categories of Pao2:Fio2 ratio (adjusted odds ratio [aOR], 2.04; 95% CI, 1.32-3.17 and aOR, 1.16; 95% CI, 0.49-2.75 for groups with Pao2:Fio2 above or equal to 80, vs. below 80, respectively; interaction p = 0.23) and OI (aOR, 1.78; 95% CI, 0.67-4.70; aOR, 3.19; 95% CI, 1.44-7.09; aOR, 1.73; 95% CI, 0.82-3.65; and aOR, 1.33; 95% CI, 0.61-2.90 for quartiles of baseline OI, respectively; interaction p = 0.44). Point estimates for the effect of HFOV were consistent across risk categories (aOR, 2.44; 95% CI, 0.40-14.83; aOR, 1.69; 95% CI, 0.75-3.85; and aOR, 2.10; 95% CI, 0.59-7.54 for the lowest, moderate, and highest risk categories, respectively; interaction p = 0.32). Using a clustering approach, point estimates for HFOV were also consistent (cluster 1: aOR, 1.85; 95% CI, 1.15-3.00 and cluster 2: aOR, 1.75; 95% CI, 0.91-3.38; interaction p = 0.75).
CONCLUSIONS: We did not identify heterogeneity in the effect of HFOV across different subgroups of patients with ARDS.
参考来源
- Kobayashi H, Angriman F, Ferguson ND, et al. Heterogeneous Treatment Effects of High-Frequency Oscillatory Ventilation for Acute Respiratory Distress Syndrome: A Post Hoc Analysis of the Oscillation for Acute Respiratory Distress Syndrome Treated Early (OSCILLATE) Trial. Crit Care Explor. 2024. PMID: 39525347. doi:10.1097/CCE.0000000000001178
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。